Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Overview

Journal Front Pharmacol

Date 2020 Apr 30

PMID 32346366

Citations 14

Authors

Miguel Piris-Villaespesa

Ivan Alvarez-Twose

Affiliations

Soon will be listed here.

Abstract

Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its ligand, the stem cell factor, KIT dimerizes activating downstream pathways involving multiple tyrosine kinases (PI3K, JAK/STAT, RAS/ERK). Activating mutations in KIT are detected in most cases of systemic mastocytosis, being the most common D816V. Therefore, since the emergence of tyrosine kinase inhibitors, KIT inhibition has been an attractive approach when facing mastocytosis treatment. Initial reports showed that only the rare D816V negative cases were responsive to tyrosine kinase inhibitors. However, the development of new tyrosine kinase inhibitors such as midostaurin or avapritinib with activity against mast cells carrying the D816V KIT mutation, has changed the landscape of this disease.

Citing Articles

A Rare Case of Acute Aleukemic Mast Cell Leukemia With Osteoblastic Lesions in the Appendicular Skeleton.

Idamakanti M, Ebaid A, Bijjam R, Bakhirev A, Mukkamalla S, Andritsos L J Hematol. 2025; 14(1):32-37.

PMID: 39935699 PMC: 11809598. DOI: 10.14740/jh1383.

Imatinib mesylate promotes melanogenesis through the modulation of p38 and MITF in murine cells.

Talapphet N, Kim M Toxicol Res. 2025; 41(1):61-70.

PMID: 39802121 PMC: 11717767. DOI: 10.1007/s43188-024-00267-8.

KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis-Associated Hematologic Neoplasm.

Medawar G, Sakalabaktula K, Magri J, Rinker E, Baratam P Case Rep Hematol. 2024; 2024:4360304.

PMID: 39649724 PMC: 11625085. DOI: 10.1155/crh/4360304.

Diarrhea-predominant irritable bowel syndrome as a masquerade for systemic mastocytosis: review article and illustrating case report.

Aljabry M Arch Med Sci. 2024; 20(4):1063-1068.

PMID: 39439696 PMC: 11493042. DOI: 10.5114/aoms/176943.

Mast cell deficiency improves cognition and enhances disease-associated microglia in 5XFAD mice.

Lin C, Herisson F, Le H, Jaafar N, Chetal K, Oram M Cell Rep. 2023; 42(9):113141.

PMID: 37713312 PMC: 10634538. DOI: 10.1016/j.celrep.2023.113141.

References

Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A . PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000; 15(1):17-28. View

Gleixner K, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C . Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007; 92(11):1451-9. DOI: 10.3324/haematol.11339. View

Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L . KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015; 29(6):1223-32. PMC: 4522520. DOI: 10.1038/leu.2015.24. View

Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris M, Elie C . Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015; 126(8):1009-16. DOI: 10.1182/blood-2014-12-614743. View

Tokarski J, Newitt J, Chang C, Cheng J, Wittekind M, Kiefer S . The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006; 66(11):5790-7. DOI: 10.1158/0008-5472.CAN-05-4187. View

Munoz-Gonzalez J, Jara-Acevedo M, Alvarez-Twose I, Merker J, Teodosio C, Hou Y . Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Adv. 2018; 2(21):2814-2828. PMC: 6234367. DOI: 10.1182/bloodadvances.2018020628. View

Alvarez-Twose I, Jara-Acevedo M, Morgado J, Garcia-Montero A, Sanchez-Munoz L, Teodosio C . Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2015; 137(1):168-178.e1. DOI: 10.1016/j.jaci.2015.05.008. View

Okayama Y, Kawakami T . Development, migration, and survival of mast cells. Immunol Res. 2006; 34(2):97-115. PMC: 1490026. DOI: 10.1385/IR:34:2:97. View

Nagata H, Worobec A, Oh C, Chowdhury B, Tannenbaum S, Suzuki Y . Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995; 92(23):10560-4. PMC: 40651. DOI: 10.1073/pnas.92.23.10560. View

10.

Cruse G, Metcalfe D, Olivera A . Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am. 2014; 34(2):219-37. PMC: 3994404. DOI: 10.1016/j.iac.2014.01.002. View

11.

Jara-Acevedo M, Teodosio C, Sanchez-Munoz L, Alvarez-Twose I, Mayado A, Caldas C . Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015; 28(8):1138-49. DOI: 10.1038/modpathol.2015.72. View

12.

Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-7. DOI: 10.1056/NEJM200104053441401. View

13.

Verstovsek S, Tefferi A, Cortes J, OBrien S, Garcia-Manero G, Pardanani A . Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008; 14(12):3906-15. PMC: 5018899. DOI: 10.1158/1078-0432.CCR-08-0366. View

14.

Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B . Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008; 80(5):456-8. DOI: 10.1111/j.1600-0609.2008.01048.x. View

15.

van Anrooij B, Oude Elberink J, Span L, de Monchy J, Rosati S, Mulder A . Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. J Allergy Clin Immunol. 2018; 142(3):1006-1008.e7. DOI: 10.1016/j.jaci.2018.06.003. View

16.

Akin C, Brockow K, DAmbrosio C, Kirshenbaum A, Ma Y, Longley B . Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003; 31(8):686-92. DOI: 10.1016/s0301-472x(03)00112-7. View

17.

Lortholary O, Chandesris M, Livideanu C, Paul C, Guillet G, Jassem E . Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017; 389(10069):612-620. PMC: 5985971. DOI: 10.1016/S0140-6736(16)31403-9. View

18.

DeAngelo D, George T, Linder A, Langford C, Perkins C, Ma J . Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2017; 32(2):470-478. DOI: 10.1038/leu.2017.234. View

19.

Gleixner K, Peter B, Blatt K, Suppan V, Reiter A, Radia D . Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013; 98(9):1450-7. PMC: 3762103. DOI: 10.3324/haematol.2012.079202. View

20.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K . The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018; 103(5):799-809. PMC: 5927976. DOI: 10.3324/haematol.2017.179895. View